Rheumatoid Arthritis Treatment Market To Stay In The Growth Quadrant

Posted by Merin John on June 8th, 2021

The Rheumatoid Arthritis Treatment Market report by Persistence Market Research focuses on the healthcare trends to be pondered about in the upcoming period. When the world at large is gripped with predictive analysis and data science, the healthcare industry cannot remain untouched. These two advancements ascertain that the doctors could monitor, access, or even intervene in real-time reports of the patients.

The Rheumatoid Arthritis Treatment Market is on the verge of reaching US$ 40.5 Bn at the rate of 6% CAGR from 2021-2031. Healthcare vertical being subject to sensitive, personal data, is at a higher risk of cyber-attacks (with the majority opting for EHR). This calls for semantic interoperability, which lets the information management systems interpret as well as derive insights through shared data. This would help in proper tracking of patients’ records in a coordinated way to out-of-network as well as in-network providers.

Rising occurrence of rheumatoid arthritis because of shift toward unhealthy lifestyle as well as increasing research & development activities for better and permanent therapy alternatives for rheumatoid arthritis treatment in order to diminish repeat rates are supporting market development. Rheumatoid arthritis is related with the immune system that leads to inflammation in the joints of the body, and later on the disease affects the muscles, fibrous tissues, tendons, and connective tissues. The load of rheumatoid arthritis (RA), currently incurable and an unending autoimmune disease that basically attacks the joints, is prominent. In 2020, approximately 4.9 million individuals across major regions were affected by rheumatoid arthritis. Manufacturers are focusing on partnerships and expansion of product portfolio by launching technologically advanced products and receiving approval from different government bodies.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22555

The global rheumatoid arthritis treatment market is estimated to be valued at US$ 40.5 Bn in 2021, and is expected to exhibit a CAGR of around 6% over the forecast period (2021 – 2031).

Key Takeaways from Market Study

• Under therapy, DMARDs hold maximum value share, owing to increasing awareness associated with their utilization.
• By distribution channel, hospital pharmacies hold a notable revenue share of more than 75% in the market.
• The market North America accounted for a share of over 40% in 2020, and is expected to experience significant growth over the next ten years.
• Europe is the next dominating region with a market share of 28% in 2020, due to well-developed healthcare infrastructure largely supported by the government.

“Rise in prevalence of rheumatoid arthritis along with increase in adoption of DMARD therapies, flourishing combination treatment, and supportive government policies are expected to drive market growth,” says a Persistence Market Research analyst.

Collaborations and Acquisitions – Imperative Strategy for Market Players

Major companies in the rheumatoid arthritis treatment market are actively engaging in acquisitions and expansions in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies are acquiring other companies who are facing a large number of product recalls in the market.

• In April 2021, Novartis signed an initial agreement with Roche to reserve capacity and implement technology transfer for the production of active pharmaceutical ingredient (API) for Roche’s Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis, which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19-associated pneumonia.
• In October 2020, Johnson & Johnson announced the successful acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovered and developed novel therapies for immune-mediated diseases.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the rheumatoid arthritis treatment market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021–2031, based on therapy (symptomatic treatment, intermediate corticosteroid therapies, stem cell therapy/ cell therapy, and disease-modifying anti-rheumatic drugs (DMARDs)) and distribution channel (hospital pharmacies, retail pharmacies, and drug stores), across seven key regions of the world.